One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosedhypertensive patients: A randomized, double-blind study

Clinical Drug Investigation

Volumn 29, Issue 9, 2009, Pages 591-600

  Parrinello, Gaspare ^c   Paterna, Salvatore ^a   Torres, Daniele ^a   Pasquale, Pietro Di ^b   Mezzero, Manuela ^a   Rocca, Gabriella La ^a   Cardillo, Mauro ^a   Trapanese, Caterina ^a   Caradonna, Mario ^a   Licata, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Ospedale GF Ingrassia   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART OUTPUT; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BISOPROLOL; DOUBLE-BLIND METHOD; FEMALE; HEART; HEART FUNCTION TESTS; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FUNCTION TESTS; LOSARTAN; MALE; MIDDLE AGED; TIME FACTORS;

EID: 68949099366     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11315250-000000000-00000     Document Type: Article

References (50)

1. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984; 26: 861-868
2. London GM, Safar ME, Sassard JE, et al. Renal and systemic haemodynamics in sustained essential hypertension. Hypertension 1984; 6: 743-754
3. Marin R, Gorostidi M, Fernandez-Vega F, et al. Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int Suppl 2005; 99: 52S-6
4. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249 (3 Pt 2): 324-327
5. Dworkin LD, Feiner HD. Glomerular injury in unine-phrectomized spontaneously hypertensive rats: a consequence of glomerular capillary hypertension. J Clin Invest 1986; 77: 797-809
6. Ljungman S, Wikstrand J, Hartford M, et al. Effects on long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension. Am J Hypertens 1993; 6 (7 Pt 1): 554-563
7. Cruickshank JM. Are we understanding beta-blockers? Int J Cardiol 2007; 120: 10-27
8. Warren DJ, Swainson CP, Wright N. Deterioration in renal function after beta-blockade in patients with chronic renal failure and hypertension. Br Med J 1974; 2: 193-194
9. Snell A, Wallace M. Beta blockade in the presence of renal disease and hypertension [letter]. Br Med J 1974; 2: 672
10. Swainson CP, Winney RJ. Effects of beta-blockade in chronic renal failure [letter]. Br Med J 1976; 1: 459
11. Waal-Manning HJ, Hendrika J. Atenolol and three non-selective beta-blockers in hypertension. Clin Pharmacol Ther 1979; 25: 8-18
12. Waal-Manning HJ, Bolli P. Atenolol versus placebo in mild hypertension: renal metabolic and stress antipressor effects. Br J Clin Pharmacol 1980; 9: 553-560
13. Johns TE, Lopez LM. Bisoprolol: is this just another beta- blocker for hypertension or angina? Ann Pharmacother 1995; 29: 403-414
14. Czuriga I, Riecansky I, Bodnar J, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther 2003; 17: 257-263
15. Paterna S, Parrinello G, Di Pasquale P, et al. Medium-term effects of bisoprolol administration on renal hemody-namics and function in mild to moderate essential hypertension. Adv Ther 2007; 24: 260-270
16. Paterna S, Parrinello G, Scaglione R, et al. Effect of long- term losartan administration on renal haemodynamics and function in hypertensive patients. Cardiovasc Drugs Therapy 2000; 14: 529-532
17. Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 2006; 20: 239-253
18. ESH-ESC guidelines of arterial hypertension 2003. J Hypertens 2003; 21: 1011-1053
19. Schlegel JU, Haway SA. Individual renal plasma flow determination in 2minutes. J Urol 1976; 111: 282-288
20. Gates GE. Glomerular filtration rate: estimation from fractional renal accumulation of 99m Tc DTPA. Am J Radiol 1981; 138: 565-570
21. Scaglione R, Ganguzza A, Corrao S, et al. Effect of cilazapril on renal haemodynamics and function in hypertensive patients: a randomised controlled study versus hydro-chlorothiazide. Blood Pressure 1995; 4: 363-368
22. Scaglione R, Indovina A, Parrinello G, et al. Anti-hypertensive efficacy and effects of nitrendipine on cardiac and renal haemodynamics in mild to moderate hypertensive patients: randomized controlled trial versus hydrochlorothiazide. Cardiovasc Drugs Ther 1992; 6: 141-146
23. Licata G, Scaglione R, Guillet C, et al. Double-blind controlled study of rilmenidine versus hydrochlorothiazide in mild hypertension: clinical and renal haemodynamic evaluation. J Hum Hypertens 1992; 6: 140-146
24. Licata G, Scaglione R, Ganguzza A, et al. Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients: a randomized controlled study versus placebo. Eur J Clin Pharmacol 1993; 45: 307-311
25. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantification of left ventricle by two dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358-367
26. Dickstein K. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT? Am Heart J 2003; 145 (5): 754-757
27. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 35: 670-674
28. Iñigo P, Campistol JM, Lario S, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12: 822-827
29. Ruilope LM, Alcazar JM, Hernandez E, et al. Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 1990; 8: 525-531
30. Parving HH, Andersen AR, Smith UM, et al. Effect of anti-hypertensive treatment on kidney function and diabetic nephropathy. BMJ 1987; 294: 1443-1447
31. Bakris GL, Hart P, Ritz E. Beta-blockers in the management of chronic kidney disease. Kidney Int 2006; 70: 1905-1913
32. Baker JG. The selectivity of b-adrenoceptor antagonist at the human b1, b2 and b3 adrenoceptors. Br J Pharmacol 2005; 144: 317-322
33. Oral I, Vareka I, Marek D. The effect of a single dose of bisoprolol on changes in blood pressure and hemodynamic indicators in patients with mild hypertension. Vnitr Lek 1992; 38: 980-985
34. Kakoki M, Hirata Y, Hayakawa H, et al. Effects of vasodilatory b-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999; 33 (1 Pt 2): 467-471
35. Goldberg M, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993; 21: 704-713
36. Uehara Y, Takada S, Hirawa N, et al. Vasoconstrictor and renal protection induced by beta 1-selective adrenoceptor antagonist bisoprolol. J Cardiovasc Pharmacol 1994; 23: 897-906
37. Leeman M, van de Borne P, Collart F, et al. Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. J Cardiovasc Pharmacol 1993; 22: 785-791
38. Aunapuu M, Pechter U, Arend A, et al. Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment. Medicina 2003; 39: 975-979
39. Gluck Z, Reubi FC. Acute changes in renal function induced by bisoprolol, a new cardioselective beta-blocking agent. Eur J Clin Pharmacol 1986; 31: 107-111
40. Loutzenhiser R, Griffin K, Williamson G, et al. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol 2006; 290: 1153-1167
41. Kvam FI, Ofstad J, Iversen BM. Effects of antihypertensive drug on autoregulation of RBF and glomerular capillary pressure in SHR. Am J Physiol 1998; 275: 576-584
42. Iversen BM, Sekse I, Ofstad J. Resetting of renal blood flow autoregulation in spontaneously hypertensive rats. Am J Physiol 1987; 252: 480-486
43. Iversen BM, Kvam FI, Matre K, et al. Resetting of renal blood autoregulation during acute blood pressure reduction in hypertensive rats. Am J Physiol Renal Physiol 1998; 275: 576-584
44. Herman WH, Emancipator SN, Rhoten RLP, et al. Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol 1998; 275 (1 Pt 2): 8F-17
45. Border WA, Noble NA, Yamamoto T, et al. Antagonists of transforming growth factor-beta: a novel approach to treatment of glomerulonephritis and prevention of glo-merulosclerosis. Kidney Int 1992; 41: 566-570
46. Deyneli O, Yavuz D, Velioglu A. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst 2006; 7: 98-103
47. Ots M, MacKenzie HS, Troy JL, et al. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998; 9: 224-230
48. Lafayette RA, Mayer G, Park SK, et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771
49. Blumenfeld JD, Sealey JE, Mann SJ. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999; 12: 451-459
50. Willenheimer R, van Veldhuisen DJ, Silke B, et al. CIBIS III Investigators. Effect on survival and hospitalization on initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS III). Circulation 2005; 112: 2426-2435